Download PDF
Endoscopy 2000; 32(9): 715-719
DOI: 10.1055/s-2000-9228
Review
Georg Thieme Verlag Stuttgart · New York

Photodynamic Therapy in Gastroenterology: Current Status in the Year 2000

H.C. Wolfsen
  • Dept. of Photodynamic Therapy and the Esophageal Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

Photodynamic therapy (PDT) involves the interaction between a photosensitizing agent and light, in the presence of oxygen, to produce photodamage to target tissue. While photodynamic therapy has been used since ancient times to treat dermatoses, it was not until the 1960s that porphyrin-based photosensitizers were first used for photodetection and phototherapy of malignancies. Thereafter, clinical experience accumulated slowly until the mid-1990s, when regulatory approval for PDT using porfimer sodium was granted in parts of North America, Europe, and Japan. This paper reviews recent clinical advances and discusses technological developments that may soon alter the way in which photodynamic therapy is used.

References

  • 1 Daniell MD, Hill JS. A history of photodynamic therapy.  Aust N Z J Surg. 1991;  61 340-348
    PubMedGoogle Scholar
  • 2 Lipson RL, Baldes EJ, Gray MJ. Hematoporphyrin derivative for detection and management of cancer.  Cancer. 1967;  20 2255-2257
    PubMedGoogle Scholar
  • 3 Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy.  J Natl Cancer Inst. 1998;  90 889-905
    CrossrefPubMedGoogle Scholar
  • 4 Kalka K, Merk H, Mukhtar H. Photodynamic therapy in dermatology.  J Am Acad Dermatol. 2000;  42 389-416
    CrossrefPubMedGoogle Scholar
  • 5 Dougherty TJ. A brief history of clinical photodynamic therapy development at Roswell Park Cancer Institute.  J Clin Laser Med Surg. 1996;  14 219-221
    PubMedGoogle Scholar
  • 6 Ell C. Clinical photodynamic therapy: where is it heading? [editorial].  Endoscopy. 1998;  30 408-411
    PubMedGoogle Scholar
  • 7 Ortner MA, Liebetruth J, Schreiber S, et al. Photodynamic therapy of nonresectable cholangiocarcinoma.  Gastroenterology. 1998;  114 536-542
    Google Scholar
  • 8 Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients.  Gastrointest Endosc. 1999;  49 1-7
    CrossrefPubMedGoogle Scholar
  • 9 Bown SG, Rogowska AZ. New photosensitizers for photodynamic therapy in gastroenterology.  Can J Gastroenterol. 1999;  13 389-392
    PubMedGoogle Scholar
  • 10 Barr H, Krasner N, Boulos PB, et al. Photodynamic therapy for colorectal cancer: a quantitative pilot study.  Br J Surg. 1990;  77 93-96
    PubMedGoogle Scholar
  • 11 Wong Kee Song LM, Wang KK, Zinsmeister AR. Mono-l-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model.  Cancer. 1998;  82 421-427
    CrossrefPubMedGoogle Scholar
  • 12 Ell C, Gossner L, May A, et al. Photodynamic ablation of early cancers of the stomach by means of mTHPC and laser irradiation: preliminary clinical experience.  Gut. 1998;  43 345-349
    PubMedGoogle Scholar
  • 13 Webber J, Herman M, Kessel D, Fromm D. Current concepts in gastrointestinal photodynamic therapy.  Ann Surg. 1999;  230 12-23
    CrossrefPubMedGoogle Scholar
  • 14 Loh CS, Bliss P, Bown SG, Krasner N. Photodynamic therapy for villous adenomas of the colon and rectum.  Endoscopy. 1994;  26 243-246
    PubMedGoogle Scholar
  • 15 Savary JF, Grosjean P, Monnier P, et al. Photodynamic therapy of early squamous cell carcinomas of the esophagus: a review of 31 cases.  Endoscopy. 1998;  30 258-265
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Gossner L, Stolte M, Sroka R, et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid.  Gastroenterology. 1998;  114 448-455
    PubMedGoogle Scholar
  • 17 Grosjean P, Wagnieres G, Fontolliet C, et al. Clinical photodynamic therapy for superficial cancer in the oesophagus and the bronchi: 514 nm compared with 630 nm light irradiation after sensitization with Photofrin II.  Br J Cancer. 1998;  77 1989-1995
    PubMedGoogle Scholar
  • 18 Hsi RA, Rosenthal DI, Glatstein E. Photodynamic therapy in the treatment of cancer: current state of the art.  Drugs. 1999;  57 725-734
    PubMedGoogle Scholar
  • 19 Abulafi AM, Allardice JT, Williams NS, et al. Photodynamic therapy for malignant tumours of the ampulla of Vater.  Gut. 1995;  36 853-856
    PubMedGoogle Scholar
  • 20 Mlkvy P, Messmann H, Debinski H, et al. Photodynamic therapy for polyps in familial adenomatous polyposis: a pilot study.  Eur J Cancer. 1995;  31A 1160-1165
    PubMedGoogle Scholar
  • 21 Millson CE, Wilson M, Macrobert AJ, et al. The killing of Helicobacter pylori by low-power laser light in the presence of a photosensitiser.  J Med Microbiol. 1996;  44 245-252
    PubMedGoogle Scholar
  • 22 Wolfsen HC, Wang KK, Ahlquist D, et al. Light dosimetry in photodynamic therapy for Helicobacter pylori. . In: Spinelli P, Dal Fante M, Marchesini R Photodynamic therapy and biomedical lasers. Amsterdam; Elsevier 1992: 281-285
    Google Scholar
  • 23 Reddi E. Role of delivery vehicles for photosensitizers in the photodynamic therapy of tumours.  J Photochem Photobiol B. 1997;  37 189-195
    CrossrefPubMedGoogle Scholar
  • 24 Sivak MV, Jr. Endoscopic technology: is this as good as it gets? [editorial].  Gastrointest Endosc. 1999;  50 718-721
    PubMedGoogle Scholar
  • 25 Bays R, Wagnieres G, Robert D, Braichotte D, Savary JF, Monnier P, van den Bergh H. Light dosimetry for photodynamic therapy in the esophagus.  Lasers Surg Med. 1997;  20 290-303
    CrossrefPubMedGoogle Scholar

M.D. H. WolfsenC. 

Division of Gastroenterology and Hepatology Mayo Clinic

Director of Photodynamic Therapy

4500 San Pablo Road

Jacksonville, FL 32224

USA

Phone: + 1-904-953-7260

Email: pdt@mayo.edu

      >